New York, NY (PRWEB) February 07, 2013
The prescription drug resource center DrugRisk.com is alerting patients taking the birth control drugs Yaz or Yasmin of new information added to the site which shows thousands of Yaz lawsuits still remain pending despite reports that thousands have already settled.
“The goal of DrugRisk is to improve patient safety by providing the latest warnings, recalls and legal action related to prescription drugs andmedical devices. By remaining informed, patients can have discussions with their doctors and decide if they need the advice of a lawyer,” explains DrugRisk representative Ryan Mayer.
The resource center has added warnings for the Bayer drugs Yaz and Yasmin from experts like the American College of Obstetricians and Gynecologists, who stated that birth control pills containing drospirenone may have a higher risk for blood clots.*
DrugRisk also discovered that thousands of patients in the U.S. havefiled a Yaz lawsuit over blood clots, which have been consolidated in a special federal Multi-District Litigation court in Illinois.**
Now, the latest report from the judicial panel on multidistrict litigation indicates that 9,455 of these cases are still pending.*** Bayer’s most recent financial statements show they have reached as many as 3,500 Yaz settlements, at an average of nearly $214,000 per case.**** Therefore, many patients have yet to receive help.
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.
However, due to the number of cases pending, the Drug Risk Resource Center cautions that victims should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits. DrugRisk will report in the future of any official Yaz recall.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*Chicago Tribune October 24, 2012, “Newer Pill has low blood clot risk: ob-gyn group”
**Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).
****Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012